Communiqués Dermata Therapeutics, Inc.

Actions

DRMA

US2498455045

Recherche biotechnologique et médicale

Temps Différé Nasdaq 16:45:25 17/09/2026			Varia. 5j.	Varia. 1 janv.
1,190 ^USD	+3,48%		-0,83%	-48,71%

11/08	Dermata Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
13/05	Dermata Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

25/08	Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment	AQ
21/08	Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch	AQ
17/08	Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
11/08	Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026	AQ
05/08	Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment	AQ
13/05	Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026	AQ
02/04	Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System	AQ
26/03	Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025	AQ
29/12	Dermata Therapeutics : Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules	PU
24/12	Dermata Therapeutics : Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules	PU
05/12	A New Realm of Skincare is Coming, Dermata Teases New OTC Brand Identity	AQ
03/10/25	Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office	AQ
18/09/25	Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025	AQ
17/09/25	Dermata Therapeutics : EADV Congress 2025 STAR-1 Abstract	PU
16/09/25	Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th	AQ
14/08/25	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results	AQ
10/06/25	Dermata Therapeutics : Corporate Presentation 2025	PU
15/04/25	Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks	AQ
28/03/25	Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules	AQ
27/03/25	BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints	PR
17/03/25	Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results	AQ
04/03/25	Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne	PR
23/01/25	Dermata Therapeutics : Announces Closing of $2.55 Million Private Placement Priced At The Market Under Nasdaq Rules	PU
23/01/25	Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market under Nasdaq Rules	AQ
22/01/25	Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari with Daxxify	AQ